Przejdź do zawartości
Merck

Przejdź do

SML2497

BIO 1211 trifluoroacetate salt

≥97% (HPLC)

Synonim(y):

2-MPUPA-LDVP trifluoroacetate, 4-(N′-(2-Methylphenyl)urea)-phenylacetyl-LDVP trifluoroacetate, BIO-1211 trifluoroacetate, BIO1211 trifluoroacetate, N-[2-[4-[[[(2-Methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-leucyl-L-α-aspartyl-L-valyl-L-proline trifluoroacetate, N-[[4-[[[(2-Methylphenyl)amino]carbonyl]amino]-phenyl]acetyl]-LDVP trifluoroacetate, N-[[4-[[[(2-Methylphenyl)amino]carbonyl]amino]-phenyl]acetyl]-Leu-Asp-Val-Pro trifluoroacetate, N-[[4-[[[(2-Methylphenyl)amino]carbonyl]amino]-phenyl]acetyl]-fibronectin CS-1 fragment (1980-1983) trifluoroacetate

Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.

Informacje o tej pozycji

Wzór empiryczny (zapis Hilla):
C36H48N6O9 · xC2HF3O2
Numer CAS:
Masa cząsteczkowa:
708.80 (free base basis)
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥97% (HPLC)
Form:
film, lyophilized powder
Storage condition:
desiccated


assay

≥97% (HPLC)

form

film, lyophilized powder

storage condition

desiccated

color

white to beige

shipped in

wet ice

storage temp.

−20°C

SMILES string

N3([C@@H](CCC3)C(=O)O)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)Cc1ccc(cc1)NC(=O)Nc2c(cccc2)C)CC(C)C)CC(=O)O)C(C)C

InChI

1S/C36H48N6O9/c1-20(2)17-26(38-29(43)18-23-12-14-24(15-13-23)37-36(51)40-25-10-7-6-9-22(25)5)32(46)39-27(19-30(44)45)33(47)41-31(21(3)4)34(48)42-16-8-11-28(42)35(49)50/h6-7,9-10,12-15,20-21,26-28,31H,8,11,16-19H2,1-5H3,(H,38,43)(H,39,46)(H,41,47)(H,44,45)(H,49,50)(H2,37,40,51)/t26-,27-,28-,31-/m0/s1

InChI key

NVVGCQABIHSJSQ-KFZSMJGVSA-N

Biochem/physiol Actions

BIO 1211 is a selective, tight-binding α4β1 (VLA-4, very late antigen-4; koff = 1.4 x 10-4/s, KD = 70 pM) integrin antagonist (VCAM-Ig Jurkat surface binding IC50 = 1 nM; integrin-mediated cell adhesion IC50 = 4 nM/α4β1, 2 μM/α4β7, >100 μM/α1β1, α5β1, α6β1, αLβ2, αIIBβ3) based on the Leu-Asp-Val (LDV) sequence from the alternatively spliced connecting segment-1 (CS-1) of fibronectin (aa 1980-1983). In addition to probing α4β1-mediated cellular responses, BIO 1211 is also widely used in animal disease models in vivo, including MS (5-10 mg/kg; murine EAE) and asthma (1-10 mg/kg via intranasal or nebulizer to mice, rats, sheep; 3 mg/sheep iv.).
Potent and selective α4β1 integrin (VLA-4) antagonist for probing α4β1-mediated cellular & pathological responses in vitro and in vivo.
Ta strona może zawierać tekst przetłumaczony maszynowo.

Porównaj podobne pozycje

Wyświetl pełne porównanie

Pokaż różnice

1 of 1

Ta pozycja
SML2885SML2094SML1928
form

film, lyophilized powder

form

lyophilized powder

form

powder

form

powder

assay

≥97% (HPLC)

assay

≥95% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

storage temp.

−20°C

storage temp.

−20°C

storage temp.

−20°C

storage temp.

2-8°C

storage condition

desiccated

storage condition

-

storage condition

desiccated

storage condition

-

color

white to beige

color

white to off-white

color

white to beige

color

white to beige

shipped in

wet ice

shipped in

-

shipped in

wet ice

shipped in

-


Klasa składowania

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

Nie widzisz odpowiedniej wersji?

Jeśli potrzebujesz konkretnej wersji, możesz wyszukać konkretny certyfikat według numeru partii lub serii.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów



K c Lin et al.
Journal of medicinal chemistry, 42(5), 920-934 (1999-03-12)
Integrin alpha4beta1 mediates leukocyte recruitment, activation, mediator release, and apoptosis inhibition, and it plays a central role in inflammatory pathophysiology. High-affinity, selective inhibitors of alpha4beta1, based on the Leu-Asp-Val (LDV) sequence from the alternatively spliced connecting segment-1 (CS-1) peptide of
Nourollah Ramroodi et al.
Immunological investigations, 44(7), 694-712 (2015-10-06)
Some functional limitations and economic burden of therapeutic antibodies indicated that introducing of alternative therapeutic compounds with same or different mechanism of action could be worthwhile. In this regard small-molecule antagonists can have a wide range of impacts, so in
W M Abraham et al.
American journal of respiratory and critical care medicine, 162(2 Pt 1), 603-611 (2000-08-10)
The leukocyte integrin very late antigen-4 (alpha(4)beta(1), CD49d/CD29) is an adhesion receptor that plays an important role in allergic inflammation and contributes to antigen-induced late responses (LAR) and airway hyperresponsiveness (AHR). In this study, we show that single doses of



Questions

Reviews

No rating value

Active Filters